Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01908777 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma
A Phase 2 study of T Cell Non-Hodgkin Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
- 10
- Study locations
NCT01908777: Completed Phase 2 study of T Cell Non-Hodgkin Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01908777 is a Phase 2 study of T Cell Non-Hodgkin Lymphoma that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 47 participants, above the 41-participant average among 5 other T Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (15% higher). The trial reports 10 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01908777, a Phase 2 study of T Cell Non-Hodgkin Lymphoma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to test the benefit of a chemotherapy drug called romidepsin in patients with T Cell Non-Hodgkin Lymphoma (T NHL) who have undergone autologous transplantation.
Primary Outcome
The progression-free survival of patients with T NHL who receive maintenance romidepsin at 2 years post-transplant for patients transplanted in CR1 or PR1 with standard risk histologies.
Conditions Studied
Interventions
- OTHER High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin
Study Locations (10)
New York
- Memorial Sloan Kettering Cancer Center @ Suffolk - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Weill Cornell Medical Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Cancer Center - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
Washington
- Fred Hutchinson Cancer Research Center (Data Collection Only) - Seattle
- University of Washington (Data Collection Only) - Seattle
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2013-07-16 |
| Est. Completion | 2025-10-03 |
| Phase | Phase 2 |
What the finished NCT01908777 record still lists
NCT01908777 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, above the 41-participant average among 5 other T Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (15% higher).
The record links to 1 condition, with T Cell Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin is the first listed.
NCT01908777 lists 10 locations in 4 states (New York, New Jersey, Washington).
Frequently Asked Questions
What is clinical trial NCT01908777 about?
NCT01908777 is a clinical study titled "A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma". The purpose of this study is to test the benefit of a chemotherapy drug called romidepsin in patients with T Cell Non-Hodgkin Lymphoma (T NHL) who have undergone autologous transplantation.
What is the current status of trial NCT01908777?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2013-07-16. Estimated completion is 2025-10-03.
What conditions does trial NCT01908777 study?
This clinical trial studies the following conditions: T Cell Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT01908777?
The interventions under investigation include: High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin (OTHER).
Who is sponsoring clinical trial NCT01908777?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01908777 being conducted?
This trial has 10 study locations across Florida, New Jersey, New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for T Cell Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma
COMPLETED · Phase 2
-
CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)
RECRUITING · Phase 1
-
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant
COMPLETED · Phase 1
-
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI